Related Experiment Video

Updated: May 18, 2026

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics
08:29

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics

Published on: October 2, 2014

17-AAG mediated targeting of Hsp90 limits tert activity in peritoneal sarcoma related malignant ascites by

M Chaklader1, P Das, J A Pereira

  • 1Stem Cell Research and Application Unit, Department of Biochemistry and Medical Biotechnology, Calcutta School of Tropical Medicine, Kolkata-700073, West Bengal, India.

Experimental Oncology
|September 28, 2012
PubMed
Abstract

Insights

The Hsp90 inhibitor 17-AAG effectively reduced malignant ascites proliferation in a mouse model. This treatment improved survival by targeting key cell cycle and DNA replication proteins, offering a potential therapy for peritoneal sarcoma.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Malignant ascites, particularly from peritoneal sarcomatosis, is a rare but severe complication of advanced cancer.
  • Heat shock protein 90 (Hsp90) plays a crucial role in stabilizing client proteins involved in cancer cell proliferation and survival.

Purpose of the Study:

  • To investigate the therapeutic effect of the Hsp90 inhibitor 17-AAG on cell cycle and DNA replication in peritoneal sarcoma-associated malignant ascites.
  • To elucidate the impact of 17-AAG on chaperone-client interactions critical for late-stage malignant growth.

Main Methods:

  • Administration of 17-AAG (an Hsp90 inhibitor) via intraperitoneal injection to mice with sarcoma-180 induced malignant ascites.
  • Evaluation included hemogram analysis, ascitic fluid cytology, cell viability, survival time, mitotic index, and flowcytometric analysis of HSP90, TERT, CyclinD1, PCNA, and GM-CSF.

Main Results:

  • 17-AAG significantly downregulated TERT and CyclinD1, crucial for cell cycle entry and DNA replication, by inhibiting Hsp90.
  • Treated malignant cells exhibited increased errors in karyokinesis, forming micronuclei and showing reduced viability.
  • 17-AAG controlled peripheral neutrophilia by downregulating GM-CSF and improved median survival time.

Conclusions:

  • 17-AAG demonstrates potential as a pharmacological agent for managing peritoneal sarcoma-related malignant ascites.
  • Targeting Hsp90 with 17-AAG may offer a strategy for prolonging survival in patients with this condition.

More Related Videos

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Anaphase Promoting Complex00:50

Anaphase Promoting Complex

The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...